Top

Osteoporosis International

Published in:

01-08-2014 | Letter

Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy

Authors: M. Ortego-Jurado, R. Ríos-Fernández, J. L. Callejas-Rubio, M. Á. Gonzalez-Gay, N. Ortego-Centeno

Published in: Osteoporosis International | Issue 8/2014

Excerpt

Dear Editor, …

Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml. Osteoporos Int 23:2479–2487PubMedCentralPubMedCrossRef

Peris P, Martinez-Ferrer A, Monegal A, Martinez de Osaba MJ, Muxi A, Guanabens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51:54–58PubMedCrossRef

Ishijima M, Sakamoto Y, Yamanaka M et al (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398–404PubMedCrossRef

Deane A, Constancio L, Fogelman I, Hampson G (2007) The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord 8:3PubMedCentralPubMedCrossRef

Stoch SA, Saag KG, Greenwald M et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714PubMedCrossRef

Reid DM, Hughes RA, Laan RF et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15:1006–1013

Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263PubMedCrossRef

Davidson ZE, Walker KZ, Truby H (2012) Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies. J Clin Endocrinol Metab 97:738–744PubMedCrossRef

Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRef

Title: Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy
Authors: M. Ortego-Jurado
R. Ríos-Fernández
J. L. Callejas-Rubio
M. Á. Gonzalez-Gay
N. Ortego-Centeno
Publication date: 01-08-2014
Publisher: Springer London
Published in: Osteoporosis International / Issue 8/2014
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2713-6

At a glance: The STEP trials

Springer Medicine

Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2014

Hand-held dynamometry fixated with a tripod is reliable for assessment of back extensor strength in women with osteoporosis

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries

Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004–2009

Physical activity throughout adolescence and bone mineral density in early adulthood: the 1993 Pelotas (Brazil) Birth Cohort Study

Testosterone levels increase in association with recovery from acute fracture in men

The effect of exercise and education on fear of falling in elderly women with osteoporosis and a history of vertebral fracture: results of a randomized controlled trial